Stock BYSI BEYONDSPRING INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BeyondSpring Inc.

Equities

BYSI

KYG108301006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.8 USD -2.70% Intraday chart for BeyondSpring Inc. -12.62% +100.00%
Apr. 15 North American Morning Briefing : Stock Futures -2- DJ
Mar. 25 BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Stock Futures -2-
DJ
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment
MT
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
AQ
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
CI
BeyondSpring Inc. Announces Executive Changes
CI
Top Premarket Decliners
MT
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
AQ
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
AQ
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements
MT
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
AQ
Transcript : BeyondSpring Inc. - Special Call
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
AQ
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity
CI
BEYONDSPRING AND PROFESSOR K. EISENMANN OF THE UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE PRESENT POSTER HIGHLIGHTING PLINABULIN'S ANTI-CANCER EFFICACY IN PRIMARY AND RECURRENT GLIOBLASTOMA PATIENT DERIVED INVASIVE NEUROSPHERE MODELS
AQ
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
SEED THERAPEUTICS DISCLOSES NOVEL MOLECULAR GLUE IND CANDIDATE FOR CANCER AT 'TARGETED PROTEIN DEGRADATION THINK TANK' SYMPOSIUM
AQ
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BYSI Stock
  4. News BeyondSpring Inc.